Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00517920 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 study of Advanced Hepatocellular Carcinoma, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
- 6
- Study locations
NCT00517920 is a Phase 2 study of Advanced Hepatocellular Carcinoma that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 44 participants, below the 85-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (48% lower). The trial reports 6 study locations across 2 states.
The verdict
NCT00517920, a Phase 2 study of Advanced Hepatocellular Carcinoma, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
- 6
- Study locations
Study Summary
Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
Conditions Studied
Interventions
- DRUG ABT-869
Study Locations (6)
Other
- Site Reference ID/Investigator# 7169 - Toronto
- Site Reference ID/Investigator# 5837 - Vancouver
- Site Reference ID/Investigator# 5235 - Singapore
- Site Reference ID/Investigator# 5611 - Singapore
- Site Reference ID/Investigator# 6265 - Taipei
Pennsylvania
- Site Reference ID/Investigator# 7726 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00517920
The ClinicalTrials.gov registry entry for NCT00517920 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 85-participant average among 16 other Advanced Hepatocellular Carcinoma trials with a reported enrollment target (48% lower). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which ABT-869 is the first listed.
NCT00517920 reports 6 study locations spanning 2 distinct geographic areas - top geographies include Other, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00517920 about?
NCT00517920 is a clinical study titled "Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)". Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)
What is the current status of trial NCT00517920?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2007-09. Estimated completion is 2012-06.
What conditions does trial NCT00517920 study?
This clinical trial studies the following conditions: Advanced Hepatocellular Carcinoma.
What interventions are being tested in trial NCT00517920?
The interventions under investigation include: ABT-869 (DRUG).
Who is sponsoring clinical trial NCT00517920?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00517920 being conducted?
This trial has 6 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer
RECRUITING · Phase 2
-
Ligufalimab and Cadonilimab in Advanced Liver Cancers
RECRUITING · Phase 2
-
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
RECRUITING · Phase 2
-
A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer
COMPLETED · Phase 2
-
CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer
COMPLETED · Phase 2
-
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.